Market Research Logo

Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) - Pipeline Review, H2 2018

Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) - Pipeline Review, H2 2018

Summary

Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) pipeline Target consti


Introduction
Global Markets Direct Report Coverage
Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) - Overview
Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) - Companies Involved in Therapeutics Development
Amgen Inc
Arena Pharmaceuticals Inc
CymaBay Therapeutics Inc
Dong-A Socio Holdings Co Ltd
Hyundai Pharmaceutical Co Ltd
Japan Tobacco Inc
Kowa Co Ltd
Merck & Co Inc
Novartis AG
Taisho Pharmaceutical Holdings Co Ltd
Yuhan Corp
Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) - Drug Profiles
APD-597 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DA-1241 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HOB-047 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MBX-2982 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SCO-094 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Agonize GPR119 for Type 2 Diabetes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Agonize GPR119 for Type 2 Diabetes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Agonize GPR119 Receptor for Unspecified Indication - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Agonize GRP119 for Type 2 Diabetes and Obesity - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize GPR119 for Type 2 Diabetes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize GPR119 for Type 2 Diabetes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize GPR119 for Type 2 Diabetes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize GPR119 Receptor for Type 2 Diabetes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
YH-18420 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) - Dormant Products
Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) - Discontinued Products
Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) - Product Development Milestones
Featured News & Press Releases
Nov 04, 2010: Arena Pharmaceuticals Provides Update On GPR119 Portfolio For Type 2 Diabetes
Nov 05, 2009: Metabolex Closes $8.6 Million Financing Round
Dec 15, 2008: Arena Pharmaceuticals Announces Initiation Of Phase I Clinical Trial Of Type 2 Diabetes Drug Candidate In Partnership With Ortho-McNeil-Janssen Pharmaceuticals
Nov 12, 2008: Metabolex Announces Positive Results From Phase 1a Clinical Trial Of MBX-2982
Mar 26, 2008: Metabolex, Inc. Initiates Phase 1 Trial Of MBX-2982
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indication, H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Number of Products under Investigation by Universities/Institutes, H2 2018
Products under Investigation by Universities/Institutes, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by Amgen Inc, H2 2018
Pipeline by Arena Pharmaceuticals Inc, H2 2018
Pipeline by CymaBay Therapeutics Inc, H2 2018
Pipeline by Dong-A Socio Holdings Co Ltd, H2 2018
Pipeline by Hyundai Pharmaceutical Co Ltd, H2 2018
Pipeline by Japan Tobacco Inc, H2 2018
Pipeline by Kowa Co Ltd, H2 2018
Pipeline by Merck & Co Inc, H2 2018
Pipeline by Novartis AG, H2 2018
Pipeline by Taisho Pharmaceutical Holdings Co Ltd, H2 2018
Pipeline by Yuhan Corp, H2 2018
Dormant Products, H2 2018
Dormant Products, H2 2018 (Contd..1), H2 2018
Discontinued Products, H2 2018
List of Figures
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report